S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Summary

The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations. \*The study sponsor has made the decision not to move forward to the expansion part of the study due to strategic considerations, unrelated to any safety issues or concerns. The study will be stopped after completion of dose escalation parts 1a and 1b of the study.

Timeline

Start

2021-10-15

Primary completion

2024-02-01

Completion

2026-05-05

Publications

• Naing A, Spreafico A, Barve M, Patnaik A, Ianopoulos X, Drean P, Skartved NJ, Hemon A, Kantari-Mimoun C, He P, Askoxylakis V, Lakhani N. Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. J Immunother Cancer. 2026 May 8;14(5):e014325. doi: 10.1136/jitc-2025-014325.

Drugs

Indications